Objective: To help perinatal health care providers identify and assist pregnant and postpartum patients with perinatal mental illness, specifically perinatal mood and anxiety disorders. Areas of focus include risk factors and identification, screening, treatment, and referral.
Target Population: All individuals who are pregnant or in the first year postpartum.
Outcomes: Open dialogue and evidence-informed care for perinatal mood and anxiety disorders, including competency for identification, screening, treatment, and referral, which will lead to improvements in patient care.
Benefits, Harms, And Costs: Pregnant and postpartum individuals with untreated perinatal mental illness, including mood and anxiety disorders, may suffer devastating effects and their family may experience short- and long-term adverse outcomes.
Evidence: A literature search was conducted using Medline (Ovid), PubMed, Embase and the Cochrane library from inception to June 2024. Additional articles were identified from article bibliographies and grey literature published by reputable societies and organizations (see online Appendix A).
Validation Methods: The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix B (Tables B1 for definitions and B2 for interpretations of strong and weak recommendations).
Intended Audience: All heath care providers who provide preconception counselling and/or care during pregnancy and the postpartum period. The term "perinatal" will be used throughout this guideline to refer to these health care providers.
Social Media Abstract: New SOGC Guideline! Identify, support, and treat perinatal mood and anxiety disorders. Focused on risk factors, screening, treatment and referrals during pregnancy and the postpartum period. Let's open dialogue and provide evidence-informed care for improved patient outcomes.
Summary Statements: RECOMMENDATIONS: IDENTIFICATION AND RISKSCREENINGTREATMENT.
Bipolar disorder (BD) is a central nervous system condition that is typified by fluctuations in mood, oscillating between depressive and manic, and/or hypomanic episodes. The objective of this study was to test the hypothesis that strength training may act as a potent protector against behavioral and neurochemical changes induced by BD. A strength training protocol was performed with adult male Wistar rats, and seven days following the conclusion of training, a single ouabain injection was administered.
Background: Modern elite football places extremely high demands on the athlete's body, so it is of practical interest to study the effect of various dietary supplements on load tolerance and postexercise recovery. Furthermore, there is a lack of research on the effects of caffeine on key measures of load tolerance in football such as delayed-onset muscle soreness (DOMS), rate of perceived exertion (RPE) and heart rate (HR) at different time points after the exercise.
Methods: 54 young players aged 15-17 years from a leading Russian football academy took part in a randomised trial using the balanced placebo design.
Escitalopram is commonly prescribed for depressive and anxiety disorders in elderly patients, who often show variable drug responses and face higher risks of side effects due to age-related changes in organ function. The CYP2C19 polymorphism may further affect escitalopram pharmacokinetics in elderly patients, complicating dose optimization for this group. Previous pharmacogenetic studies examining the impact of CYP2C19 phenotype on escitalopram treatment outcomes have primarily focused on younger adults, leaving a gap in understanding its effects on the elderly.
Background: Psoriatic arthritis (PsA) is a chronic inflammatory condition that can affect individuals of all ages. Patients may experience a range of physical and psychological issues.
Objective: To examine the impact of PsA on an individual's quality of life (QoL) and physical function.
